Comparing the Two Top Stocks: Scana Corporation (NYSE:SCG), Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Scana Corporation (NYSE:SCG)

Scana Corporation (NYSE:SCG) closed at $47.78 on the last trading session with an increase of 0%, whereas, it previously closed at $47.78. The company has a market capitalization of $7.2 Billion. The company traded shares of 0 on the trading day while its three month average volume stands at 2.08 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Scana Corporation (NYSE:SCG) produced diluted EPS of -1.2. The EPS estimate for next year as estimated by analysts is at 2.7 while EPS for next quarter is estimated at 0.51. Earnings per Share growth for this year is reported at -114.9, while the analysts estimated the EPS growth for next year at 2.7% and Earnings growth for next 5 years stands at 4% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -17.1%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Scana Corporation (NYSE:SCG) is at 0 while the forward p/e is at 17.72. The P/S or Price to Sales ratio of Scana Corporation (NYSE:SCG) stands at 1.75 and Price to Book or P/B for the most recent quarter stands at 1.27. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Scana Corporation (NYSE:SCG) are reported at 1 and 1.2 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Scana Corporation (NYSE:SCG) stands at -1.1, -3.8 and 1.8 respectively

The trailing twelve month Revenue of Scana Corporation (NYSE:SCG) is reported at 4.11 Billion with income of -171000000. The outstanding shares of Scana Corporation (NYSE:SCG) are 150.67 Million. The institutional Ownership of the shares of 71.1 stands at 0.80%, this figure is decreased -1.62 in the last six months. The insider ownership for the shares of Scana Corporation (NYSE:SCG) is ticked at 5.26%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Scana Corporation (NYSE:SCG) is the Mean Target Price estimated by the analysts which stands at 49.38. The 52 week high of Scana Corporation (NYSE:SCG) is placed at 51.27 and 52 week low is standing at 33.61.

Performance wise the shares of Scana Corporation (NYSE:SCG) fell down -4.08% for the week, it also rise 4.94% for the monthly performance, while for the quarter it went down 22.86%. The shares increase 24.04% for the half year and flew up for the Year-To-Date performance. The shares of Scana Corporation (NYSE:SCG) grew 20.29% for the yearly performance.

Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Intellia Therapeutics, Inc. (NASDAQ:NTLA) closed at $13.7 on the last trading session with an increase of 0.37%, whereas, it previously closed at $13.65. The company has a market capitalization of $564.58 Million. The company traded shares of 557027 on the trading day while its three month average volume stands at 696.24 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) produced diluted EPS of -2.16. The EPS estimate for next year as estimated by analysts is at -2.52 while EPS for next quarter is estimated at -0.54. Earnings per Share growth for this year is reported at -31.8, while the analysts estimated the EPS growth for next year at -2.52% and Earnings growth for next 5 years stands at 30% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at 0%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Intellia Therapeutics, Inc. (NASDAQ:NTLA) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands at 19.33 and Price to Book or P/B for the most recent quarter stands at 2.25. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Intellia Therapeutics, Inc. (NASDAQ:NTLA) are reported at 11.5 and 11.5 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands at -25.8, -31.7 and -23.1 respectively

The trailing twelve month Revenue of Intellia Therapeutics, Inc. (NASDAQ:NTLA) is reported at 29.2 Million with income of -90200000. The outstanding shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) are 41.21 Million. The institutional Ownership of the shares of 68.5 stands at 0.80%, this figure is increased 1.1 in the last six months. The insider ownership for the shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) is ticked at 28.44%, the figure is plummeted -0.06% in the last six months.

Some other important financial aspects to be discussed here for Intellia Therapeutics, Inc. (NASDAQ:NTLA) is the Mean Target Price estimated by the analysts which stands at 39.79. The 52 week high of Intellia Therapeutics, Inc. (NASDAQ:NTLA) is placed at 35.99 and 52 week low is standing at 11.03.

Performance wise the shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) rose up 14.17% for the week, it also fell -21.76% for the monthly performance, while for the quarter it went up -49.5%. The shares decrease -52.31% for the half year and flew up for the Year-To-Date performance. The shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) shrinked -28.72% for the yearly performance.